Trial · NCT00939770
Adverse events3,280
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 3,280
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal distension | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID | 0 | 6 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID | 1 | 8 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID | 3 | 23 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID | 0 | 12 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID | 5 | 38 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID | 1 | 11 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID | 3 | 14 | |
| other | Abdominal distension | Gastrointestinal disorders | Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID | 0 | 10 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID | 2 | 6 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID | 1 | 8 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID | 13 | 23 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID | 2 | 12 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 280 mg/m2/Dose BID | 18 | 38 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 1: Part A: PF-02341066 365 mg/m2/Dose BID | 3 | 11 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2: Part B: PF-02341066 280 mg/m2/Dose BID | 7 | 14 | |
| other | Abdominal pain | Gastrointestinal disorders | Phase 2: Part C: PF-02341066 280 mg/m2/Dose BID | 2 | 10 | |
| other | Abducens nerve disorder | Nervous system disorders | Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID | 0 | 6 | |
| other | Abducens nerve disorder | Nervous system disorders | Phase 1: Part A: PF-02341066 130 mg/m²/Dose BID | 0 | 8 | |
| other | Abducens nerve disorder | Nervous system disorders | Phase 1: Part A: PF-02341066 165 mg/m²/Dose BID | 2 | 23 | |
| other | Abducens nerve disorder | Nervous system disorders | Phase 1: Part A: PF-02341066 215 mg/m²/Dose BID | 0 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00939770/events